CD44
CD44 Informations sur la molécule
| Nom anglais | CD44 antigen | Nombre de médicaments commercialisés | 0 |
| Nombre de médicaments cliniques | 10 | Alias de la cible | Hermes Antigen，Hyaluronate Receptor，Cell Surface Glycoprotein CD44，MC56，PGP-1，CD44，CDW44，GP90 Lymphocyte Homing/Adhesion Receptor，MIC4，LHR，Hematopoietic Cell E- And L-Selectin Ligand，CD44 Antigen (Homing Function And Indian Blood Group System)，MDU3，Extracellular Matrix Receptor III，Heparan Sulfate Proteoglycan，HUTCH-I，ECMR-III，Epican，Chondroitin Sulfate Proteoglycan 8，Soluble CD44，MDU2，Pgp1，CSPG8，HCELL，Phagocytic Glycoprotein 1，Indian Blood Group Antigen，IN，Phagocytic Glycoprotein I，CD44 Molecule (Indian Blood Group)，CD44 Antigen，PGP-I，Homing Function And Indian Blood Group System，Hyaluronan Receptors，CD44R |
| Phase de R&D la plus avancée | Phase 3 Clinical | ||
| Nom anglais | CD44 antigen |
| Alias de la cible | Hermes Antigen，Hyaluronate Receptor，Cell Surface Glycoprotein CD44，MC56，PGP-1，CD44，CDW44，GP90 Lymphocyte Homing/Adhesion Receptor，MIC4，LHR，Hematopoietic Cell E- And L-Selectin Ligand，CD44 Antigen (Homing Function And Indian Blood Group System)，MDU3，Extracellular Matrix Receptor III，Heparan Sulfate Proteoglycan，HUTCH-I，ECMR-III，Epican，Chondroitin Sulfate Proteoglycan 8，Soluble CD44，MDU2，Pgp1，CSPG8，HCELL，Phagocytic Glycoprotein 1，Indian Blood Group Antigen，IN，Phagocytic Glycoprotein I，CD44 Molecule (Indian Blood Group)，CD44 Antigen，PGP-I，Homing Function And Indian Blood Group System，Hyaluronan Receptors，CD44R |
| Nombre de médicaments commercialisés | 0 |
| Nombre de médicaments cliniques | 10 |
| Phase de R&D la plus avancée | Phase 3 Clinical |
CD44 Liste de produits
- Attribut
Protein (2)Antibody (2)
- Bibliothèque de produits
En ligne (4)
- Espèces
Human (2)Rabbit (1)Mouse (1)
- Étiquette
His Tag (1)Fc Tag (1)- (2)
- Marqueur
Unconjugated (3)PE Labeled (1)
| Numéro de produit | Espèces | Système d'expression | Description du produit | Structure protéique | Pureté | Caractéristiques | Pré-commande/Commande |
|---|---|---|---|---|---|---|---|
 Human | HEK293 | Human CD44 Protein, His Tag |  |  |  |  Ajouter au panier | |
| Human | HEK293 | Human CD44 Protein, Fc Tag (HPLC verified) |  | | | Ajouter au panier | |
 Mouse | - | PE-Labeled Monoclonal Anti-Human CD44 Antibody, Mouse IgG1 (AS625) (0.03% Proclin) |  | Ajouter au panier | |||
 Rabbit | - | Recombinant Monoclonal Anti-CD44 Antibody, Rabbit (5G3) | Ajouter au panier |
Quantité totale4
- 1
CD44Alias de la molécule
CD44,CDW44,CSPG8,ECMR-III,HCELL,HUTCH-I,IN,LHR,MC56,MDU2,MDU3,MIC4,Pgp1,Epican
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Paclitaxel/Hyaluronic acid | Phase 3 Clinical | Fidia Pharma | Carcinoma, Papillary; Urinary Bladder Neoplasms | Details | |
| CA-102N | CA-102N | Phase 2 Clinical | Holy Stone Healthcare Co Ltd | Colorectal Neoplasms; Solid tumours | Details |
| P-134 | P-134; P134 | Phase 2 Clinical | Tianjin Tasly Pharmaceutical Co Ltd | Glioblastoma | Details |
| Rosuvastatin liposome encapsulated therapy (Beijing Inno Medicine) | YN001; YN-001 | Phase 2 Clinical | Beijing Inno Medicine Co Ltd | Atherosclerosis; Cardiovascular Diseases; Cerebrovascular Disorders; Coronary Artery Disease; Erectile Dysfunction | Details |
| AMT-116(Multitude Therapeutics) | AMT-116; AMT-116-ADC | Phase 2 Clinical | Multitude Therapeutics Inc | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Solid tumours | Details |
| Hyaluronic acid/Fluorouracil | HA-5FU; HA-5-fluorouracil; Hyaluronic acid-5-fluorouracil complex; Hyaluronan acid-5-fluorouracil complex | Phase 2 Clinical | Alchemia Ltd, Monash University | Colorectal Neoplasms | Details |
| AMC-303 | AMC-303; HP-558 | Phase 1 Clinical | Amcure Gmbh | Esophageal Squamous Cell Carcinoma; Solid tumours | Details |
| Clodronic acid/Hyaluronic acid | Phase 1 Clinical | Abiogen Pharma Spa | Osteoarthritis | Details | |
| 177Lu-AKIR001 | 177Lu-AKIR001 | Phase 1 Clinical | Akiram Therapeutics AB | Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Neoplasms; Thyroid Carcinoma, Anaplastic; Uterine Cervical Neoplasms; Vulvar Neoplasms | Details |
| BGC-0228 | BGC-0228 | Phase 1 Clinical | Brightgene Bio-Medical Technology Co Ltd | Solid tumours | Details |
- Informations sur la molécule
- Liste de produits
- Informations sur les médicaments cliniques